Incidence, mortality, and survival trends of ovarian cancer in hong kong, 1997 to 2006: A populationbased study

Hong Kong Medical Journal

Volumn 18, Issue 6, 2012, Pages 466-474

  Wong, K H ^a   Mang, O W K ^a   Au, K H ^a   Law, S C K ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Epidemiologic studies; Incidence; Mortality; Ovarian neoplasms; Survival

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOLOGY; HONG KONG; HUMAN; INVASIVE EPITHELIAL OVARIAN CARCINOMA; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; POPULATION RESEARCH; SURVIVAL RATE; TREND STUDY;

AGE FACTORS; AGED; COHORT STUDIES; FEMALE; HONG KONG; HUMANS; INCIDENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; REGISTRIES; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84872182200     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Hong Kong Cancer Stat 2009. Hong Kong Cancer Registry, Hospital Authority website: http://www3.ha.org.hk/cancereg. Accessed 31 Oct 2011.
2. Chia KS, Du WB, Sankaranarayanan R, Sankila R, Seow A, Lee HP. Population-based cancer survival in Singapore, 1968 to 1992: an overview. Int J Cancer 2001;93:142-7.
3. Yeole BB, Kumar AV, Kurkure A, Sunny L. Population-based survival from cancers of breast, cervix and ovary in women in Mumbai, India. Asian Pac J Cancer Prev 2004;5:308-15.
4. Cheung FY, Mang OW, Law SC. A population-based analysis of incidence, mortality, and stage-specific survival of cervical cancer patients in Hong Kong: 1997-2006. Hong Kong Med J 2011;17:89-95.
5. Pecorelli S, Favalli G, Zigliani, Odicino F. Cancer in women. Int J Gynaecol Obstet 2003;82:369-79.
6. Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol 2010;11:165-73.
7. Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization; 2000.
8. Pecorelli S, Ngan HY, Hacker NF, et al. Staging classifications and clinical practice guidelines for gynaecological cancers. a collaboration between FIGO and IGCS. 3rd ed. London: FIGO; 2006.
9. Segi M. Cancer mortality for selected sites in 24 countries (1950-1957). Sendai, Japan: Tohuku University of Medicine; 1960.
10. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med 2004;23:51-64.
11. Brenner H, Gefeller O, Hakulinen T. Period analysis for 'upto- date' cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 2004;40:326-35.
12. Hong Kong life tables 2004. Hong Kong: Demographic Statistics Section, Census and Statistics Department, HKSAR Government.
13. Hong Kong life tables 2007. Hong Kong: Demographic Statistics Section, Census and Statistics Department, HKSAR Government.
14. Hong Kong life tables 2010. Hong Kong: Demographic Statistics Section, Census and Statistics Department, HKSAR Government.
15. Dickman P, Hakulinen T, Voutilainen E. Surv3 relative survival analysis program version 3.00b2. Finnish Cancer Registry: Helsinki, Finland; 2002.
16. Cox DR. Regression models and life tables. J Royal Stat Soc B 1972;34:187-200.
17. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
18. Hong Kong women in figures 2007. Hong Kong: Women's Commission; 2007.
19. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R; EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009;45:931-91.
20. Rachet B, Maringe C, Nur U, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of NHS cancer plan for England. Lancet Oncol 2009;10:351-69.
21. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER Stat survival data 2001-2007, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; April 2011.
22. Kant AK, Glover C, Horm J, Schatzkin A, Harris TB. Does cancer survival differ for older patients? Cancer 1992;70:2734-40.
23. Akeson M, Jakobsen AM, Zetterqvist BM, Holmberg E, Brannstrom M, Horvath G. A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors. Int J Gynecol Cancer 2009;19:116-23.
24. Maas HA, Kruitwagen RF, Lemmens VE, Goey SH, Janssen- Heijnen ML. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a populationbased study. Gynecol Oncol 2005;97:104-9.
25. Cress RD, O'Malley CD, Leiserowitz GS, Campleman SL. Pattern of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol 2003;21:1530-5.
26. Bruchim I, Altaras M, Fishman A. Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol 2002;86:274-8.
27. Guppy AE, Nathan PD, Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol) 2005;17:399-411.
28. Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009;113:775-82.
29. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
30. National Comprehensive Cancer Network Practice Guidelines in Oncology: ovarian cancer and genetic screening. Available from: http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed 17 Sep 2011.
31. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361:170-7.
32. Gaarenstroom KN, van der Hiel B, Tollenaar RA, et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 2006;16 Suppl 1:54-9.
33. Hamidou Z, Causeret S, Dabakuyo TS, et al. Populationbased study of ovarian cancer in Cote d'Or: prognostic factors and trends in relative survival rates over the last 20 years. BMC Cancer 2010;10:622-9.
34. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003;189:1120-7.
35. Cooper N, Quinn MJ, Rachet B, Mitry, Coleman MP. Survival from cancer of the ovary in England and Wales up to 2001. Br J Cancer 2008;99 Suppl 1:S70-2.
36. Verdecchia A, Guzzinati S, Francisci S, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009;45:1042-66.
37. Averette HE, Janicek MF, Menck HR. The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1995;76:1096-103.
38. Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analysis of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998;78:1479-87.
39. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
40. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatincyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
41. Sundararajan V, Hershman D, Grann VR, Jacobson JS, Neugut AI. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 2002;20:173-8.
42. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28:3107-14.
43. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-71.
44. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.